Overview Show
Practice EssentialsBeta-adrenergic antagonist (ie, beta-blocker) toxicity can produce clinical manifestations including bradycardia, hypotension, arrhythmias, hypothermia, hypoglycemia, and seizures (see the images below). The presentation may range from asymptomatic to shock.  Beta-blockers have been in use for nearly 50 years. In addition to their traditional role in treating hypertension and other cardiovascular disorders, beta-blockers are also used for additional purposes such as migraine headaches, hyperthyroidism, glaucoma, anxiety, and various other disorders. As a result of their expanded use, the incidence of overdose with these agents has also increased. Beta-blocker toxicity in children usually results from exposure to an adult's unattended medications. Beta-blocker toxicity in adults usually results from a suicide attempt or an accidental overdose of a routine medication. PathophysiologyUnderstanding the direct and indirect effects of beta-receptor blockade is crucial to rapid identification and appropriate treatment of beta-blocker toxicity. Beta-blockers act as competitive inhibitors of catecholamines, exerting their effects at both central and peripheral receptors. Blockade of beta-receptors results in decreased production of intracellular cyclic adenosine monophosphate (cAMP) with a resultant blunting of multiple metabolic and cardiovascular effects of circulating catecholamines. Beta1-receptor blockade reduces heart rate, blood pressure, myocardial contractility, and myocardial oxygen consumption. Beta2-receptor blockade inhibits relaxation of smooth muscle in blood vessels, bronchi, the gastrointestinal system, and the genitourinary tract. In addition, beta-adrenergic receptor antagonism inhibits both glycogenolysis and gluconeogenesis, which may result in hypoglycemia. Other than the direct effects of the beta-adrenoreceptor blockade, toxicity may result from other mechanisms, including sodium and calcium channel blockade, centrally mediated cardiac depression, and alteration of cardiac myocyte energy metabolism. [1] Numerous beta-blockers are available; these agents comprise a heterogeneous drug family with varying toxicologically relevant characteristics. An understanding of these different characteristics is helpful for understanding the clinical presentations with particular agents and for guiding therapy. Nonselective activityPropranolol was the first beta-blocker to enter widespread use; much of the clinical and overdose experience that exists with beta-blockers was provided by case reports and clinical studies of this drug. Propranolol is a nonselective beta-blocker, demonstrating equal affinity for both beta1- and beta2-receptors. Other nonselective beta-blockers include nadolol, timolol, and pindolol. Nonselective beta-blockers exert a wider variety of extracardiac manifestations. Intrinsic sympathomimetic activitySome beta-blockers, such as pindolol and acebutolol, also have beta-agonist properties. Although their agonist property is weaker than that of catecholamines, they are capable of stimulating beta-receptors, especially when catecholamine levels are low. Of note, acebutolol has been reported to be particularly lethal in overdose. Membrane-stabilizing activityBeta-blockers, such as propranolol, labetalol, and pindolol, can have membrane-stabilizing activity (MSA; eg, the quinidine-like effects of the class IA antidysrhythmic effects). MSA blocks myocyte sodium channels. This property, usually not evident at therapeutic doses, may significantly contribute to toxicity by prolonging QRS duration and impairing cardiac conduction. Seizures are more commonly observed in drugs with MSA. Beta-blockers with MSA are associated with the largest proportion of fatalities. Lipid solubilityLipid solubility is higher in agents such as propranolol and carvedilol, but lower in agents such as atenolol and nadolol. It may influence the degree of central nervous system (CNS) effects and utility of hemodialysis or hemoperfusion. [2] High lipid solubility leads to a larger volume of distribution and better CNS penetration. Lipophilic beta-blockers are primarily metabolized by the liver. Propranolol is among these, and its active metabolite (4-OH propranolol) prolongs its biological activity. Conversely, hydrophilic beta-blockers have a small volume of distribution and are eliminated essentially unchanged by the kidneys; this property allows hydrophilic beta-blockers to be removed by hemodialysis. QT-interval prolongationThe electrophysiologic effects of sotalol deserve special consideration. Unlike other beta-blockers, sotalol has antidysrhythmic properties consistent with the type III antidysrhythmic agents. Class III agents prolong the action potential duration and the effective refractory period of AV and atrioventricular myocytes, which can lengthen the QT-interval duration and result in polymorphic ventricular tachycardia (ie, torsade de pointes). Ventricular dysrhythmias associated with sotalol toxicity can occur up to 48 hours postingestion. EpidemiologyPropranolol is the most toxic beta-blocker and the most frequently used in suicide attempts worldwide. The 2019 Annual Report of the American Association of Poison Control Centers' (AAPCC) National Poison Data System reported 11,166 single exposures to beta-blockers. Of the reported exposures, 2699 were in children younger than 6 years, and 7131 were in adults 20 years of age and older. Approximately 80% of exposures were unintentional. [3] PrognosisPrognosis is largely dependent on the initial response to therapy (6-12 h postingestion) as drug levels are likely to have peaked at this time. In addition, beta-blockers that are lipid soluble and have marked antidysrhythmic (ie, quinidine-like) effects are more lethal (eg, propranolol, sotalol, oxprenolol). Underlying cardiac or pulmonary disease places the patient at increased risk for poor outcome. The outcome is significantly worse when these agents are co-ingested with psychotropic or cardioactive drugs. This is true even if the amount of beta-blocker ingested is relatively small. The co-ingestants that most markedly worsen prognosis include calcium channel blockers, cyclic antidepressants, and neuroleptics. These co-ingestions are the most important factor associated with the development of cardiovascular morbidity and mortality. According to the 2019 AAPCC, beta-blockers were the seventh leading cause of fatal exposure and the following numbers of outcomes in 10,398 cases of beta-blocker exposure were reported [3] :
Author Coauthor(s) Lemeneh Tefera, MD, FAAEM Attending Physician, Department of Emergency Medicine, Beth Israel Medical Center Lemeneh Tefera, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine Disclosure: Nothing to disclose. Aman Aminzay, MD Attending Physician, Department of Emergency Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine Aman Aminzay, MD is a member of the following medical societies: American College of Emergency Physicians Disclosure: Nothing to disclose. Chief Editor Additional Contributors Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital Disclosure: Nothing to disclose. Acknowledgements John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society Disclosure: Nothing to disclose. David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine Disclosure: Nothing to disclose. John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists Disclosure: Nothing to disclose. Acknowledgments The authors and editors of Medscape Reference gratefully acknowledge the medical review of this article by Lada Kokan, MD. What are the adverse effects of propranolol?Common side effects. headaches.. feeling tired, dizzy or weak.. cold fingers or toes.. feeling or being sick (nausea or vomiting), or diarrhoea.. stomach pain.. What are the adverse effects of betaSide effects of beta blockers
feeling tired, dizzy or lightheaded (these can be signs of a slow heart rate) cold fingers or toes (beta blockers may affect the blood supply to your hands and feet) difficulties sleeping or nightmares. feeling sick.
What are the main cardiac adverse effects of betaCommon side effects of beta blockers can include: Cold hands or feet. Fatigue. Weight gain.. Depression.. Shortness of breath.. Trouble sleeping.. What are three complications of propranolol?The more common side effects of propranolol can include:. slower heart rate.. diarrhea.. dry eyes.. hair loss.. nausea.. weakness or tiredness.. |
Which symptoms are serious adverse effects of beta adrenergic blockers such as propranolol?
zusammenhängende Posts
Urheberrechte © © 2024 ihoctot Inc.
